![Benjamin Yerxa](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 3 M $ al 31/05/2026
Benjamin R.
Yerxa was the founder of Opus Genetics, Inc. (2021, Chief Executive Officer 2022-2024) and Envisia Therapeutics, Inc. (2013, President 2013-2017).
Current jobs include Chairman at RainBio, Inc., Independent Director at Clearside Biomedical, Inc. (2022), Director at The North Carolina Biotechnology Center (2008), Director at Vedere Bio II, Inc., President & Director at Opus Genetics, Inc. (2024), and Director at Nacuity Pharmaceuticals, Inc. (2019).
Former jobs include Chief Executive Officer at The Foundation Fighting Blindness, Inc. (2017-2022), Chief Executive Officer at Retinal Degeneration Fund (2018-2022), Director at SparingVision SAS (2017-2022), EVP, Chief Research & Development Officer at Inspire Pharmaceuticals, Inc. (2009-2010), Research Scientist at Burroughs Wellcome, Vice President-Product Development at Parion Sciences, Inc. (2010-2011), Vice President-Research & Development at Clearside Biomedical, Inc. (2011-2012), and Chief Scientific Officer at Liquidia Technologies, Inc. (2012-2015).
Education includes a doctorate from the University of California, Irvine (1993) and an undergraduate degree from the University of California San Diego (1988).
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
OPUS GENETICS, INC. 0,87 % | 23/04/2026 | 711.535 ( 0,87 % ) | 3 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CLEARSIDE BIOMEDICAL | Director/Miembro de la Junta | 03/03/2022 |
| OPUS GENETICS, INC. | Presidente | 22/10/2024 |
Nacuity Pharmaceuticals, Inc.
 Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Director/Miembro de la Junta | 01/10/2019 |
RainBio, Inc.
 RainBio, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapy for corneal treatments | Presidente | - |
Vedere Bio II, Inc.
 Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Develops ocular gene therapy | Director/Miembro de la Junta | - |
The North Carolina Biotechnology Center
 The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services Provides research and education grants | Director/Miembro de la Junta | 01/11/2010 |
| Empresas | Cargo | Fin |
|---|---|---|
Opus Genetics, Inc.
 Opus Genetics, Inc. BiotechnologyHealth Technology Provides clinical stage gene therapies for inherited retinal diseases | Director Ejecutivo | 01/01/2024 |
Retinal Degeneration Fund
 Retinal Degeneration Fund Investment Trusts/Mutual FundsMiscellaneous Operates as a fund focuses on making mission-related investments in companies with projects nearing clinical testing | Director Ejecutivo | 01/07/2022 |
The Foundation Fighting Blindness, Inc.
 The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services Provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome | Director Ejecutivo | 01/07/2022 |
| ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░ ░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 17 |
|---|---|
Inspire Pharmaceuticals, Inc.
 Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Health Technology |
Parion Sciences, Inc.
 Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Commercial Services |
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Develops particle-based vaccines and therapeutics for prevention and treatment of human disease | Health Technology |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The North Carolina Biotechnology Center
The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services Provides research and education grants | Technology Services |
The Foundation Fighting Blindness, Inc.
The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services Provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome | Commercial Services |
Burroughs Wellcome | |
Clearside Biomedical, Inc.
 Clearside Biomedical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures suprachoroidal space injections for eye diseases | Health Technology |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Health Technology |
Nacuity Pharmaceuticals, Inc.
Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology Develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa | Health Technology |
Retinal Degeneration Fund
Retinal Degeneration Fund Investment Trusts/Mutual FundsMiscellaneous Operates as a fund focuses on making mission-related investments in companies with projects nearing clinical testing | Miscellaneous |
Ocuphire Pharma, Inc.
 Ocuphire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceuticals for eye disorders | Health Technology |
RainBio, Inc.
RainBio, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapy for corneal treatments | Health Technology |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Develops ocular gene therapy | Commercial Services |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Provides clinical stage gene therapies for inherited retinal diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
